Compare Coinbase Global, Inc. (COIN) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coinbase Global, Inc. vs BIO-TECHNE Corp — how do they compare? Coinbase Global, Inc. trades at $148.72 (market cap $39.23B), while BIO-TECHNE Corp trades at $72.16 (market cap $11.24B). The key difference: Coinbase Global, Inc. is far larger — about 3.5× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Coinbase Global, Inc. pays none. Which is the better fit depends on your goals.
| COIN | TECH | |
|---|---|---|
Market Cap | $39.23B | $11.24B |
Sector | Technology | Health |
52-Week High | $387.27 | $72.29 |
52-Week Low | $141.09 | $43.31 |
Enterprise Value | $36.88B | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COIN trades at $153.6, up 5.63% in the past 24 hours, but technical indicators signal a bearish trend with resistance near $157. The company reported Q2 2026 revenue of $1.22 billion, missing estimates, and a net loss of $359.5 million, though adjusted EBITDA remained positive for the 14th consecutive quarter. Analyst consensus is a Buy with a $207.20 price target, but recent news highlights crypto market weakness and a Zacks Strong Sell rating on August 6, 2026.
The outlook is mixed: strong cash flow and market share growth offer upside, but consecutive earnings misses and high valuation ratios pose risks. Investors face volatility from crypto market dependence and competitive pressures, requiring caution despite Wall Street's bullish average target.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Coinbase Global, Inc.
Coinbase Global, Inc. is a regulated cryptocurrency company that provides customers around the world with a platform for buying, selling, transferring, and storing digital assets. The Company offers a variety of products and services that enable individuals, businesses, and developers to participate in the cryptoeconomy.
Read more on COIN →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
